Lifetime Citizen Portal Access — AI Briefings, Alerts & Unlimited Follows
Arizona study committee opens review of AHCCCS coverage for obesity treatments
Loading...
Summary
At a first meeting, an Arizona legislative study committee heard ADHS prevalence data and clinical testimony urging recognition of obesity as a chronic disease and broader coverage of treatments such as counseling, bariatric surgery and GLP‑1 medications; AHCCCS staff said GLP‑1s are covered for diabetes after documented treatment failure and the agency will supply utilization and cost data to the committee.
A newly convened Arizona legislative study committee opened its review of whether the Arizona Health Care Cost Containment System (AHCCCS) should expand coverage for obesity treatment, hearing from state public‑health staff and clinicians who said both prevention and treatment can reduce long‑term costs.
At the committee’s first meeting, Emily Morey of the Arizona Department of Health Services’ Bureau of Nutrition and Physical Activity said obesity is “a risk multiplier for nearly every major chronic disease,” and presented state data showing roughly 30.5% of Arizona adults meet the clinical definition of obesity (body mass index of 30 or higher) — about 1.5 million people, according to ADHS’s BRFSS‑derived figures. Morey argued that upstream prevention — improved food access, breastfeeding supports, child‑care nutrition standards and community design that enables activity — is more cost‑effective than treating advanced disease later.
Clinical witnesses told the committee that treating obesity as a chronic disease makes a case for coverage beyond the current limits. Dr. Doug Maready, an Arizona obesity‑medicine specialist, said the committee must weigh “the suffering and disability of our patients” alongside return‑on‑investment calculations and noted recent federal cost announcements that, he said, make broader coverage more financially feasible. Maready urged Arizona to consider aligning state coverage with federal changes and to include both medical and surgical options in coverage discussions.
Steve Berg, legislative specialist for AHCCCS (sometimes referred to in the meeting as ACCESS), reviewed current program policy and told members that AHCCCS requires managed‑care organizations to operate chronic‑condition programs and that medical nutritional therapy and bariatric surgery are covered when medically necessary. Berg said AHCCCS does not currently cover GLP‑1 medications specifically for obesity; GLP‑1 agents are covered for type 2 diabetes, but only after documented failure of non‑GLP‑1 treatments such as metformin.
On clinical specifics, Dr. Karen Raman (medical director, Access for Pediatrics and Population Health) told the committee that the treatment‑failure threshold for diabetes treatment typically requires at least 90 days on metformin at a minimum dose of 1,500 mg (unless contraindicated) and an A1C above 6.5% before advancing to GLP‑1 therapy; other diabetes medications are trialed before moving to higher‑cost agents. Committee members and clinicians debated why some agents (for example, Trulicity) appear on formularies while others (Ozempic, Mounjaro) are less available, with staff saying pharmacy‑panel decisions balance clinical effect and cost.
Several providers cautioned that medications and surgery are not standalone solutions. Clinicians, dietitians and legislators emphasized multidisciplinary care including registered dietitians, behavioral health, and community supports; Amy McAllister, a registered dietitian, said nutrition counseling is an inexpensive, high‑value component of long‑term care. Multiple speakers also discussed stigma and genetics as drivers of obesity that insurance policy should reflect when setting eligibility and coverage rules.
Lawmakers asked AHCCCS to provide utilization and cost data on current GLP‑1 use and projected costs in the state plan. Berg said the agency is pulling those numbers and will provide vetted figures at the next hearing. The committee tentatively scheduled a follow‑up meeting for Nov. 25 to hear patient and provider perspectives and the requested cost modeling.
The meeting ended with no formal votes; members instructed staff to gather data and invite additional stakeholders to the next session. The committee’s final report is due by Dec. 31, 2025, to legislative leadership and the governor.
